Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Rhea-AI Summary
Evotec (NASDAQ: EVO; Frankfurt: EVT) released preliminary, unaudited figures for Q2 and the first half of 2026 and revised its full-year 2026 outlook. For H1 2026, Evotec expects Group revenues of about €300.1 million and adjusted Group EBITDA of about -€42.7 million, with liquidity around €465.6 million as of 30 June 2026.
For full-year 2026, Evotec now forecasts Group revenues of approximately €570–610 million (€595–635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER. Previous guidance was €700–780 million (€730–810 million CER) for revenues and €0–40 million (€10–50 million CER) for adjusted EBITDA.
Positive
- H1 2026 revenues approximately €300.1 million
- Liquidity at 30 June 2026 approximately €465.6 million
- FY 2026 revenue guidance still €570–610 million
Negative
- FY 2026 revenue guidance cut from €700–780 million to €570–610 million
- FY 2026 adjusted EBITDA outlook reduced from €0–40 million to -€70 to -105 million
- H1 2026 adjusted EBITDA preliminary loss of approximately -€42.7 million
News Explained
Evotec’s preliminary first-half figures accompany a full-year outlook that now includes negative adjusted EBITDA, with €465.6 million of liquidity expected at June 30, 2026.
Evotec announced preliminary, unaudited second-quarter and first-half 2026 results and an updated full-year outlook, changing the company’s stated revenue and adjusted EBITDA expectations while leaving the final results pending.
For the first half, Evotec expects approximately
Liquidity as of
News Market Reaction – EVO
On the day this news was published, EVO declined 12.75%, reflecting a significant negative market reaction. Argus tracked a trough of -26.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $147M from the company's valuation, bringing the market cap to $1.01B at that time. Trading volume was very high at 4.6x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | platform launch | Positive | +0.0% | Launch of J.TRAIN turnkey continuous biologics manufacturing solution for partners. |
| Jun 11 | AGM results | Neutral | +4.2% | Annual General Meeting approvals and Supervisory Board elections in Hamburg. |
| Jun 02 | leadership appointment | Positive | -3.9% | Appointment of Rui Wang as EVP, Head of Global In Silico and AI. |
| May 12 | convertible bond issue | Negative | -9.5% | Placement of €116.1 million senior unsecured convertible bonds due 2033. |
| May 04 | partner milestone | Positive | +1.0% | Nomination of first preclinical development candidate in Almirall dermatology collaboration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions have been mixed, with several strategic or operational updates showing price moves that diverged from the apparent news tone.
Key Terms
ebitda financial
liquidity financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately
Reflecting these factors, Evotec now expects full-year 2026 Group revenues of approximately
Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419
View original content:https://www.prnewswire.com/news-releases/ad-hoc-evotec-announces-preliminary-second-quarter-and-first-half-2026-results-and-updates-full-year-2026-outlook-302824155.html
SOURCE Evotec SE